GT Molecular Secures CDC Contract for Assay Development
GT Molecular, Inc. has recently reached a major milestone by securing a contract with the Centers for Disease Control (CDC). This agreement relates to the National Wastewater Surveillance System (NWSS) and focuses on the development, optimization, validation, and support of multi-pathogen assays. The company is known for its ultrasensitive PCR assays, which are specifically tailored for wastewater-based epidemiology, pathogen detection, and cancer research.
A Commitment to Public Health
This contract, which can last up to five years, highlights how crucial wastewater testing is for monitoring public health threats. GT Molecular plans to leverage its advanced technology to address emerging health challenges through careful wastewater surveillance.
Expanding Testing Capabilities
One goal of the project is to cover a broad spectrum of targets, including viral, bacterial, parasitic, fungal, and other significant pathogens. By incorporating multi-pathogen detection into their assays, GT Molecular is set to improve the landscape of wastewater testing.
Advancements in PCR Technology
GT Molecular has become a leader in developing user-friendly and efficient digital PCR technologies. Their innovative GT-Plex™ technology is capable of detecting even the smallest amounts of target nucleic acids, leading to sensitive and precise results.
Broadening Applications
These assays are not limited to wastewater testing alone. The company is broadening its offerings to include multiplexed PCR kits designed to detect various pathogens, oncology genes, and antimicrobial resistance (AMR). Through these advancements, GT Molecular is dedicated to pushing forward public health diagnostics.
Enhancing Partnerships and Support
This initiative will also see thousands of academic, commercial, and public testing laboratories around the world benefiting from GT Molecular's expertise and accurate PCR assay kits. The company's goal is to not only improve testing accuracy but also to provide systems that can be rapidly deployed in various testing settings.
Getting In Touch
GT Molecular invites anyone interested in their assay kits or updates regarding CDC releases to reach out. Their commitment to innovation in wastewater surveillance is backed by a readiness to collaborate and share knowledge with the community.
Frequently Asked Questions
What is the purpose of the CDC contract awarded to GT Molecular?
The contract is centered on developing and optimizing multi-pathogen assays to improve wastewater testing for public health monitoring.
How long will the contract with the CDC last?
The contract is expected to last for up to five years, during which various public health threats will be observed.
What technologies does GT Molecular use for their assays?
GT Molecular employs its patented GT-Plex™ technology, which facilitates multiplexed digital PCR assays that can detect multiple pathogens at once.
What types of pathogens will the assays cover?
The assays are designed to detect a variety of pathogens, including viral, bacterial, parasitic, and fungal species, along with antimicrobial resistance markers.
How can I learn more about GT Molecular's offerings?
For more information, interested individuals can contact GT Molecular directly or visit their official website for updates and details about their products and services.
